Tyra Biosciences Receives Buy Rating – Key 2026 Data Ahead
Tyra Biosciences’ dabogratinib shows promise: works well for bladder cancer & dwarfism with fewer side effects. Big 2026 trials ahead.
NOTRELOAD AI
Jefferies Upgrades Twilio to Buy, Raises Price Target to $160
Jefferies upgraded Twilio to Buy, seeing big potential in its Voice AI, which could boost growth and profits over the coming years.
BofA Warns Petrochemical Stocks May Have Risen Too Far, Too Fast
BofA downgraded Dow, LyondellBasell, and Westlake, saying recent gains from high oil prices may not last and stocks could slow down.
Goldman Sachs Sees 26% Upside in Netflix Stock Ahead of Q1 Earnings
Goldman Sachs upgraded Netflix to Buy, seeing strong growth, rising users, and ~26% upside despite recent stock decline.
BofA Turns Neutral on Carvana Amid Rising Oil Prices
BofA cut Carvana to Neutral: higher gas and rates hurt buyers, so upside is limited and risks are now evenly balanced.
Neurocrine Expands Rare Disease Portfolio with $2.9B Soleno Buy
Neurocrine will buy Soleno for $2.9B, adding VYKAT XR, the first drug for extreme hunger in rare Prader-Willi syndrome.